Paclitaxel combined with ifosfamide in anthracycline-and docetaxel-pretreated metastatic breast cancer: Activity independence of prior docetaxel resistance

Yong Wha Moon, Joo Hyuk Sohn, Hye Jin Choi, Hyun Chang, Byeongwoo Park, Seung Il Kim, Seho Park, JaSeung Koo, Yong Tai Kim, Jae Kyung Roh, Hyuncheol Chung, Joo Hang Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: We evaluated the efficacy and tolerability of combined paclitaxel and ifosfamide in anthracycline-and docetaxel-pretreated metastatic breast cancer (MBC). Methods:Patients received paclitaxel (175 mg/m 2 i.v. in a 3-h infusion) on day 1 and ifosfamide (1.5 g/m 2 i.v. in a 15-min infusion) on days 1-3, every 3 weeks for a maximum of nine cycles. The tumor response was assessed every two cycles. Results: We enrolled 34 patients with a median age of 50 years. Thirty patients had visceral metastases. Anthracycline-and docetaxel-based chemotherapy had previously been administered to 18/13 and 13/21 patients, respectively, in (neo)adjuvant/metastatic settings. Three patients had not previously received anthracycline due to abnormal cardiac functions. A total of 174 cycles of chemotherapy were delivered with a median of six cycles. The response rate under the intent-to-treat analysis was 23.5% (all partial responses) with a median response duration of 14 months. The disease control rate was 70.6%. The median progression-free and overall survival were 5.9 and 8.5 months, respectively. There was no apparent relationship between activity and prior docetaxel resistance. The incidence of grade III/IV neutropenia was 46.6% (81 of 174 cycles) with febrile neutropenia of only 1.7%. Major grade III/IV nonhematological toxicities included peripheral neuropathy (6 of 34 patients) and infection (4 of 34 patients). There were no treatment-related deaths. Conclusion:Paclitaxel combined with ifosfamide was effective and tolerable in anthracycline-/docetaxel-pretreated MBC. Overcoming docetaxel resistance by using paclitaxel in combination with ifosfamide needs to be addressed through further investigation.

Original languageEnglish
Pages (from-to)425-431
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume66
Issue number3
DOIs
Publication statusPublished - 2010 Aug 1

Fingerprint

docetaxel
Ifosfamide
Anthracyclines
Paclitaxel
Breast Neoplasms
Chemotherapy
Disease control
Drug Therapy
Febrile Neutropenia
Toxicity
Tumors
Peripheral Nervous System Diseases
Neutropenia
Disease-Free Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Moon, Yong Wha ; Sohn, Joo Hyuk ; Choi, Hye Jin ; Chang, Hyun ; Park, Byeongwoo ; Kim, Seung Il ; Park, Seho ; Koo, JaSeung ; Kim, Yong Tai ; Roh, Jae Kyung ; Chung, Hyuncheol ; Kim, Joo Hang. / Paclitaxel combined with ifosfamide in anthracycline-and docetaxel-pretreated metastatic breast cancer : Activity independence of prior docetaxel resistance. In: Cancer Chemotherapy and Pharmacology. 2010 ; Vol. 66, No. 3. pp. 425-431.
@article{b84d4dbb684641a4b501e5c07635a985,
title = "Paclitaxel combined with ifosfamide in anthracycline-and docetaxel-pretreated metastatic breast cancer: Activity independence of prior docetaxel resistance",
abstract = "Background: We evaluated the efficacy and tolerability of combined paclitaxel and ifosfamide in anthracycline-and docetaxel-pretreated metastatic breast cancer (MBC). Methods:Patients received paclitaxel (175 mg/m 2 i.v. in a 3-h infusion) on day 1 and ifosfamide (1.5 g/m 2 i.v. in a 15-min infusion) on days 1-3, every 3 weeks for a maximum of nine cycles. The tumor response was assessed every two cycles. Results: We enrolled 34 patients with a median age of 50 years. Thirty patients had visceral metastases. Anthracycline-and docetaxel-based chemotherapy had previously been administered to 18/13 and 13/21 patients, respectively, in (neo)adjuvant/metastatic settings. Three patients had not previously received anthracycline due to abnormal cardiac functions. A total of 174 cycles of chemotherapy were delivered with a median of six cycles. The response rate under the intent-to-treat analysis was 23.5{\%} (all partial responses) with a median response duration of 14 months. The disease control rate was 70.6{\%}. The median progression-free and overall survival were 5.9 and 8.5 months, respectively. There was no apparent relationship between activity and prior docetaxel resistance. The incidence of grade III/IV neutropenia was 46.6{\%} (81 of 174 cycles) with febrile neutropenia of only 1.7{\%}. Major grade III/IV nonhematological toxicities included peripheral neuropathy (6 of 34 patients) and infection (4 of 34 patients). There were no treatment-related deaths. Conclusion:Paclitaxel combined with ifosfamide was effective and tolerable in anthracycline-/docetaxel-pretreated MBC. Overcoming docetaxel resistance by using paclitaxel in combination with ifosfamide needs to be addressed through further investigation.",
author = "Moon, {Yong Wha} and Sohn, {Joo Hyuk} and Choi, {Hye Jin} and Hyun Chang and Byeongwoo Park and Kim, {Seung Il} and Seho Park and JaSeung Koo and Kim, {Yong Tai} and Roh, {Jae Kyung} and Hyuncheol Chung and Kim, {Joo Hang}",
year = "2010",
month = "8",
day = "1",
doi = "10.1007/s00280-009-1176-5",
language = "English",
volume = "66",
pages = "425--431",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

Paclitaxel combined with ifosfamide in anthracycline-and docetaxel-pretreated metastatic breast cancer : Activity independence of prior docetaxel resistance. / Moon, Yong Wha; Sohn, Joo Hyuk; Choi, Hye Jin; Chang, Hyun; Park, Byeongwoo; Kim, Seung Il; Park, Seho; Koo, JaSeung; Kim, Yong Tai; Roh, Jae Kyung; Chung, Hyuncheol; Kim, Joo Hang.

In: Cancer Chemotherapy and Pharmacology, Vol. 66, No. 3, 01.08.2010, p. 425-431.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Paclitaxel combined with ifosfamide in anthracycline-and docetaxel-pretreated metastatic breast cancer

T2 - Activity independence of prior docetaxel resistance

AU - Moon, Yong Wha

AU - Sohn, Joo Hyuk

AU - Choi, Hye Jin

AU - Chang, Hyun

AU - Park, Byeongwoo

AU - Kim, Seung Il

AU - Park, Seho

AU - Koo, JaSeung

AU - Kim, Yong Tai

AU - Roh, Jae Kyung

AU - Chung, Hyuncheol

AU - Kim, Joo Hang

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Background: We evaluated the efficacy and tolerability of combined paclitaxel and ifosfamide in anthracycline-and docetaxel-pretreated metastatic breast cancer (MBC). Methods:Patients received paclitaxel (175 mg/m 2 i.v. in a 3-h infusion) on day 1 and ifosfamide (1.5 g/m 2 i.v. in a 15-min infusion) on days 1-3, every 3 weeks for a maximum of nine cycles. The tumor response was assessed every two cycles. Results: We enrolled 34 patients with a median age of 50 years. Thirty patients had visceral metastases. Anthracycline-and docetaxel-based chemotherapy had previously been administered to 18/13 and 13/21 patients, respectively, in (neo)adjuvant/metastatic settings. Three patients had not previously received anthracycline due to abnormal cardiac functions. A total of 174 cycles of chemotherapy were delivered with a median of six cycles. The response rate under the intent-to-treat analysis was 23.5% (all partial responses) with a median response duration of 14 months. The disease control rate was 70.6%. The median progression-free and overall survival were 5.9 and 8.5 months, respectively. There was no apparent relationship between activity and prior docetaxel resistance. The incidence of grade III/IV neutropenia was 46.6% (81 of 174 cycles) with febrile neutropenia of only 1.7%. Major grade III/IV nonhematological toxicities included peripheral neuropathy (6 of 34 patients) and infection (4 of 34 patients). There were no treatment-related deaths. Conclusion:Paclitaxel combined with ifosfamide was effective and tolerable in anthracycline-/docetaxel-pretreated MBC. Overcoming docetaxel resistance by using paclitaxel in combination with ifosfamide needs to be addressed through further investigation.

AB - Background: We evaluated the efficacy and tolerability of combined paclitaxel and ifosfamide in anthracycline-and docetaxel-pretreated metastatic breast cancer (MBC). Methods:Patients received paclitaxel (175 mg/m 2 i.v. in a 3-h infusion) on day 1 and ifosfamide (1.5 g/m 2 i.v. in a 15-min infusion) on days 1-3, every 3 weeks for a maximum of nine cycles. The tumor response was assessed every two cycles. Results: We enrolled 34 patients with a median age of 50 years. Thirty patients had visceral metastases. Anthracycline-and docetaxel-based chemotherapy had previously been administered to 18/13 and 13/21 patients, respectively, in (neo)adjuvant/metastatic settings. Three patients had not previously received anthracycline due to abnormal cardiac functions. A total of 174 cycles of chemotherapy were delivered with a median of six cycles. The response rate under the intent-to-treat analysis was 23.5% (all partial responses) with a median response duration of 14 months. The disease control rate was 70.6%. The median progression-free and overall survival were 5.9 and 8.5 months, respectively. There was no apparent relationship between activity and prior docetaxel resistance. The incidence of grade III/IV neutropenia was 46.6% (81 of 174 cycles) with febrile neutropenia of only 1.7%. Major grade III/IV nonhematological toxicities included peripheral neuropathy (6 of 34 patients) and infection (4 of 34 patients). There were no treatment-related deaths. Conclusion:Paclitaxel combined with ifosfamide was effective and tolerable in anthracycline-/docetaxel-pretreated MBC. Overcoming docetaxel resistance by using paclitaxel in combination with ifosfamide needs to be addressed through further investigation.

UR - http://www.scopus.com/inward/record.url?scp=77954663052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954663052&partnerID=8YFLogxK

U2 - 10.1007/s00280-009-1176-5

DO - 10.1007/s00280-009-1176-5

M3 - Article

C2 - 20012956

AN - SCOPUS:77954663052

VL - 66

SP - 425

EP - 431

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -